Princess Margaret Cancer Centre, Toronto, ON, Canada
Andrew McPartlin , Ali Hosni , Philippe L. Bedard , Aaron Richard Hansen , Michael A.S. Jewett , Robert James Hamilton , Martin O'Malley , Joan Sweet , Padraig Richard Warde , Peter W. M. Chung
Background: Surveillance is recommended for patients with stage I seminoma post orchidectomy but CT imaging involves ionising radiation, with risk of associated secondary malignancies. We assessed site of disease relapse during surveillance to guide development of a risk adapted imaging protocol. Methods: Data was obtained from a prospectively maintained database of patients with stage I seminoma on surveillance after orchidectomy from 1981-2011. Relapse was determined by clinical and/or radiographic finding with or without pathological confirmation or tumour marker elevation. Results: 753 patients were identified. The median age at orchidectomy was 33.7 years. With a median follow up of 10.5 years, range 1.1-30.1, 115 (15.3%) patients relapsed. Relapse was detected radiologically in 114 (99.1%), with 9 (7.8%) having simultaneously elevated tumour markers. A clinical diagnosis of relapse was made in 1 case (inguinal node – 0.9%). The location and time to relapse are shown in table. Conclusions: In stage I seminoma surveillance, pelvic nodal relapse was restricted to the early period of follow up. Excluding the pelvis during CT imaging after the third year of surveillance may optimise the detection of relapse whilst minimising total radiation exposure. This has now been adopted at our centre since 2011 without any subsequent late pelvic relapses.
Time of relapse | Number of relapses (%) | Location of nodal relapse | ||||||
---|---|---|---|---|---|---|---|---|
Inguinal | Pelvic | PA | Inguinal and PA | Inguinal and mediastinal | Pelvic and PA | PA and Mediastinal nodes | ||
Year 1 | 52 (45.2) | 1 | 3 | 41 | 2 | 1 | 3 | 1 |
Year 2 | 34 (29.6) | 1 | 1 | 29 | 3 | |||
Year3 | 13 (11.2) | 1 | 10 | 2 | ||||
Year 4-5 | 8 (7.0) | 8 | ||||||
Year 6-9 | 7 (6.1) | 7 | ||||||
Year >9 | 1 (0.9) | 1 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Genitourinary Cancers Symposium
First Author: Robert A Huddart
2024 ASCO Genitourinary Cancers Symposium
First Author: Alok Tewari
2023 ASCO Annual Meeting
First Author: Lucia Nappi
2023 ASCO Genitourinary Cancers Symposium
First Author: Mario Fontes-Sousa